Skip to content

Creative Medical Technology Holdings, Inc.: 10-Q filed 2017-08-14

What Creative Medical Technology Holdings, Inc. reported in its quarterly report filed 2017-08-14 (fiscal Q2 2017): 24 published measures, 70 facts as tagged in accession 0001144204-17-042898.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-14
Fiscal period
fiscal Q2 2017
Accession
0001144204-17-042898 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Creative Medical Technology Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-30299,617USD
At 2016-12-31322,512USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-06-301,322,192USD
At 2016-12-31480,303USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-30104,396USD
At 2016-12-31221,868USD
At 2016-06-3025,762USD
At 2015-12-31100USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-886,356USD91
2017-01-01 to 2017-06-30-1,129,707USD181
2016-04-01 to 2016-06-30-209,247USD91
2016-01-01 to 2016-06-30-357,092USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-04-01 to 2017-06-300USD91
2017-01-01 to 2017-06-300USD181
2016-04-01 to 2016-06-300USD91
2016-01-01 to 2016-06-300USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-1,896,279USD
At 2016-12-31-766,572USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-04-01 to 2017-06-30140,957USD91
2017-01-01 to 2017-06-30142,423USD181
2016-04-01 to 2016-06-300USD91
2016-01-01 to 2016-06-300USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-886,356USD91
2017-01-01 to 2017-06-30-1,129,707USD181
2016-04-01 to 2016-06-30-209,247USD91
2016-01-01 to 2016-06-30-357,092USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-30104,396USD
At 2016-12-31221,868USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-04-01 to 2017-06-3063,240USD91
2017-01-01 to 2017-06-3065,745USD181
2016-04-01 to 2016-06-301,150USD91
2016-01-01 to 2016-06-301,866USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-301,313,920USD
At 2016-12-31453,864USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-06-3053,204USD
At 2016-12-3166,385USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2017-06-30195,221USD
At 2016-12-31100,644USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-04-01 to 2017-06-30395,991USD91
2017-01-01 to 2017-06-30636,837USD181
2016-04-01 to 2016-06-30208,097USD91
2016-01-01 to 2016-06-30355,226USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-3025,189USD91
2017-01-01 to 2017-06-3085,020USD181
2016-04-01 to 2016-06-3018,028USD91
2016-01-01 to 2016-06-3022,392USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-30106,313,750shares
At 2016-12-31105,013,750shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2017-06-30-1,022,575USD
At 2016-12-31-157,791USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-06-309,869USD
At 2016-12-314,879USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30368,016USD91
2017-01-01 to 2017-06-30546,394USD181
2016-04-01 to 2016-06-30187,576USD91
2016-01-01 to 2016-06-30328,752USD182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2017-04-01 to 2017-06-302,786USD91
2017-01-01 to 2017-06-305,423USD181
2016-04-01 to 2016-06-302,493USD91
2016-01-01 to 2016-06-304,082USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-490,365USD91
2017-01-01 to 2017-06-30-492,870USD181
2016-04-01 to 2016-06-30-1,150USD91
2016-01-01 to 2016-06-30-1,866USD182

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2017-01-01 to 2017-06-300USD181
2016-01-01 to 2016-06-300USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-06-30100,000USD181
2016-01-01 to 2016-06-300USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-13,181USD181
2016-01-01 to 2016-06-301,319USD182

Inspect the source

Entity
Creative Medical Technology Holdings, Inc. / CIK 0001187953
Captured
2026-09-20T07:45:17.099Z
SEC response SHA-256
89e881c0f2d97477b4adfc3e19e7ae581dc54b90e3254331c852038e8d4c6961

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001187953.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))